Executive pay and 71% insider stake at Pulse Biosciences (NASDAQ: PLSE)
Pulse Biosciences (PLSE) filed an amended annual report (10-K/A) detailing executive compensation, board composition, and governance, including significant insider ownership. CEO Paul A. LaViolette's 2025 compensation was approximately $7.4 million, largely equity-based with performance and market-driven vesting conditions, while CFO Jon Skinner received about $2.8 million. Director Robert W. Duggan beneficially owns 71.6% of outstanding common stock, with all directors and executive officers collectively holding 74.7%, indicating highly concentrated ownership.
How this was made
The 30-second read
Why it matters
The high insider stake suggests potential influence over company decisions, which could impact governance quality and investor confidence.
Market read
The detailed insider ownership and executive compensation disclosures provide insights into corporate governance but have limited immediate trading implications.
What to watch
Lack of recent financial performance data limits comprehensive assessment; governance quality and future performance are critical unknowns.
Background
Pulse Biosciences filed an amended annual report revealing detailed executive compensation and significant insider ownership, notably by Director Robert W. Duggan.
Ticker impact
The news is highly relevant to Pulse Biosciences due to detailed insider ownership and executive compensation disclosures.
Limited short-term price movement expected; potential for long-term stability or volatility depending on governance developments.
While insider ownership is high, the lack of immediate financial performance data limits precise short-term price predictions. The detailed compensation and ownership structure may influence investor perceptions over time.
Market effects
Potential governance concerns may influence investor confidence in the life sciences sector.
Minimal regional impact; company-specific news.
Low; company-specific governance details unlikely to affect global markets.
Counterpoint
High insider ownership may indicate strong management control, potentially aligning interests with shareholders and reducing agency risks.
Key entities
- CompanyPulse Biosciences
A life sciences company specializing in bioelectric medicine technologies.
- IndividualRobert W. Duggan
Beneficial owner holding 71.6% of outstanding common stock, indicating significant control.
- IndividualPaul A. LaViolette
CEO with approximately $7.4 million compensation in 2025, largely equity-based.
- IndividualJon Skinner
CFO with approximately $2.8 million compensation in 2025.
